| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $675.0M | +39.9% |
| Cost of Revenue | $10.9M | +67.9% |
| R&D Expense | $246.9M | +33.9% |
| SG&A Expense | $280.3M | +52.1% |
| Operating Income | $137.0M | +27.7% |
| Pre-tax Income | $161.5M | +29.7% |
| Income Tax | $20.3M | +10.1% |
| Net Income | $141.2M | +33.0% |
| EPS (Basic) | $1.35 |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $127.7M | -5.8% |
| Short-term Investments | $255.7M | +9.9% |
| Accounts Receivable | $54.0M | +31.3% |
| Inventory | $12.4M | +60.6% |
| Current Assets | $471.6M | +2.8% |
| Total Assets | $840.6M | +35.2% |
| Current Liabilities | $140.8M | +34.7% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | $198.1M | +55.9% |
| Capital Expenditures | $2.2M | +1462.6% |
| Investing Cash Flow | -$177.6M | -295.4% |
| Financing Cash Flow | -$28.3M | +80.9% |
| Free Cash Flow | $195.9M | +54.4% |
| +32.4% |
| EPS (Diluted) | $1.23 | +30.9% |
| Total Liabilities |
| $161.0M |
| +40.2% |
| Stockholders' Equity | $679.6M | +34.1% |